pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·3h ago·1 min read
save

Nonprofit North Star Review Board offers independent model to fix IRB oversight issues

Aug 11, 2026·read at STAT ↗RegulatoryNeutral

Founders Stephen Rosenfeld and Patricia Seymour created the not‑for‑profit North Star Review Board after becoming disillusioned with the current system of institutional review boards (IRBs) that oversee human research.

They argue that IRBs have drifted from their core mission of protecting research participants, citing a series of scandals over the past two decades that have eroded public trust.

A 2009 Government Accountability Office test highlighted a vulnerability when a for‑profit IRB approved a fabricated high‑risk device study, exposing how commercial pressures can compromise ethical review.

North Star proposes a nonprofit model intended to provide more independent oversight, aiming to restore confidence in the ethical review process for researchers and sponsors alike.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “IRBs have a problem. Can North Star’s nonprofit model save it?”

read at STAT ↗
2,665 words · retrieved 2h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
University of Minnesota2University of Pennsylvania2Johns Hopkins UniversityMoonLake ImmunotherapeuticsNOVARTISNational Institutes of HealthRISINGROCHE
topics
Oncology3AsthmaCRO/CDMOCardiologyCystic FibrosisGene Therapy (AAV)Heart Failure

related stories

  • 20h agoaTyr will cut 60% of workforce, Arpeggio shuttersBioSpace
  • Dec 22Fierce Biotech Fundraising Tracker '26: LifeMine raises $188M; Expedition encounters $115MFierce Biotech
  • 20h agoSTAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatmentSTAT
  • 20h agoSTAT+: FDA panel to weigh Grail’s Galleri testSTAT
  • 4d agoOpinion: One year since Kennedy canceled mRNA vaccine projects, science shows how wrong he wasSTAT